Skip to content

Developing an Objective Measure of Experienced Pain

Developing an Objective Measure of Experienced Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05415423
Enrollment
330
Registered
2022-06-13
Start date
2022-06-06
Completion date
2022-09-26
Last updated
2022-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Acute

Keywords

Measurement of Pain, Pain

Brief summary

Pain is a public health challenge around the world. However, there is no single standardized measure of pain, to the point that the estimated prevalence of chronic pain in adults ranges between 2% and 64% depending on the methods and definitions used. Existing measures of pain are known to present several problems and results can be hardly compared between people. The investigators propose and empirically validate a new, simple method to measure experienced pain in clinical trials. The method provides an objective, cardinal measurement of experienced pain which is comparable between people and the investigators test whether it is better able to measure experienced pain than existing procedures. The investigators test the new method in healthy participants using standard protocols (electrical and heat stimuli). The investigators also aim to validate the measure using a causal manipulation which relies on the administration of a topical analgesic product compared to a placebo.

Detailed description

The aim of this study is to establish and validate the proposed method of measuring pain using different pain stimuli. The investigators correlate these measurements with physiological data such as skin-conductance, heart-rate variability, pupil dilation, and with established measures of pain such as Numeric rating scale (NRS), Visual analog scale (VAS), general Labeled Magnitude Scale (gLMS). In addition, the investigators study the test-retest reliability of our measure of pain and its ability to capture a reduction in experienced pain due to a topical analgesic product compared to a placebo treatment.

Interventions

BEHAVIORALDeveloping an objective measure of experienced pain

At the beginning of each study, participants are randomly allocated into one of two groups. Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research. Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics.

Sponsors

Balgrist University Hospital
CollaboratorOTHER
University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* age 18-60 years. * ability and willingness to participate in the study * declaration of consent * good English language skills (to ensure understanding of all instructions and the declaration of consent).

Exclusion criteria

* inability to give the declaration of consent (e.g. due to linguistic difficulties understanding the study information) * any neurological disorders * reduced general health / chronic diseases (e.g. autoimmune disease, severe cardiovascular diseases, insulin-dependent diabetes, severe depression); chronic pain disorders * pregnancy * in the week before the experimental session self-reported intake of drugs which could influence pain perception (e.g. cannabis and ADHD medications).

Design outcomes

Primary

MeasureTime frameDescription
response timesbaselineResponse times relative to participants' choices between monetary amounts and painful stimuli
self-reported pain ratings according to Numerical Rating Scale (NRS)baselineself-reported pain ratings according to Numerical Rating Scale
self-reported pain ratings according to Visual Analogue Scale (VAS)baselineself-reported pain ratings according to Visual Analogue Scale
self-reported pain ratings according to general Labeled Magnitude Scale (gLMS)baselineself-reported pain ratings according to general Labeled Magnitude Scale
Choices between monetary amounts and painful stimulibaselineParticipants' choices between monetary amounts and painful stimuli

Secondary

MeasureTime frameDescription
skin conductancebaselinevariation in skin conductance in reaction to the painful stimuli.
pupil dilationbaselinevariation in pupil dilation in reaction to the painful stimuli.
heart rate variabilitybaselinevariation in heat-beat rate in reaction to the painful stimuli.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026